The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
PerspectivesFull Access

Brexpiprazole: A New Antipsychotic Following in the Footsteps of Aripiprazole

In this issue, Correll and colleagues (1) present results from a 6-week placebo-controlled trial comparing three doses of a new antipsychotic, brexpiprazole, in schizophrenia patients experiencing an acute exacerbation. They found that all three doses were well tolerated and that daily doses of 2 mg and 4 mg, but not 0.5 mg, were effective. This study provides a comprehensive picture of short-term efficacy and tolerability in relation to placebo, but in the absence of an active comparator it is difficult to predict whether brexpiprazole has meaningful advantages or disadvantages compared with existing agents. Brexpiprazole arrives at a time when many of the existing second-generation agents, including aripiprazole, have become generic—this shift toward generic agents has had a significant impact on current and projected health care budgets (2).

Brexpiprazole, like aripiprazole, is a partial agonist at dopamine D2 receptors. By activating D2 receptors to a lesser degree than endogenous dopamine, partial agonists lower the ceiling for maximal D2 transmission while increasing activity at hypoactive D2 receptors. The intent is to achieve a balance such that D2 receptors are activated sufficiently to prevent neurologic side effects (extrapyramidal symptoms) and hyperprolactinemia while avoiding excessive D2 activity, which would compromise antipsychotic efficacy and might produce side effects associated with D2 agonism. An earlier unsuccessful D2 partial agonist, bifeprunox, had greater intrinsic activity at D2 receptors than aripiprazole and was less effective than existing antipsychotics while producing nausea and vomiting attributable to D2 receptor activation (3). It might be expected that aripiprazole, as a partial agonist, also would be less effective than other antipsychotics that are D2 antagonists; however, the limited available data from head-to-head comparisons suggests that aripiprazole resides in the middle of the pack of second-generation antipsychotics in terms of efficacy (4). Aripiprazole is essentially free of hyperprolactinemia and extrapyramidal symptoms, but nausea, insomnia, and restlessness, which may be symptoms of D2 agonism, can complicate early treatment in some patients.

The relative intrinsic D2 activity of brexpiprazole was 43% compared with 61% for aripiprazole, 84% for bifeprunox, and 100% for dopamine as determined by the maximum inhibitory effect on forksolin-induced cAMP in human D2-expressing cells (5). This level of D2 activity places brexpiprazole between aripiprazole and D2 antagonist antipsychotics. All else being equal, one would predict that brexpiprazole would possess an intermediate level of efficacy and risk for extrapyramidal symptoms and prolactin elevation. However, unlike aripiprazole, brexpiprazole also has a high affinity for serotonin 5-HT1a receptors, where it is a partial agonist, and for 5-HT2a and alpha 1b and 2c adrenoceptors, where it is a potent antagonist (5). This profile makes brexpiprazole more similar to other second-generation antipsychotics than is aripiprazole and might reduce risk for extrapyramidal symptoms and improve efficacy, although this remains to be established.

The efficacy of 2- and 4-mg/day dosages of brexpiprazole in this study was robust despite a relatively large placebo response and included improvements in positive and negative symptoms and global outcome measures. However, in a similar 6-week placebo-controlled trial of brexpiprazole (the BEACON trial), only the 4-mg/day dose, and not the 2-mg/day dose, separated from placebo (6). Side effects were similar in both studies, with the 4-mg dose associated with moderate weight gain of approximately 1 kg over 6 weeks and small increases in prolactin concentrations. Akathisia occurred in 7.2% of subjects treated with 4 mg/day of brexpiprazole versus 2.2% of those receiving placebo in the study reported by Correll and colleagues (1), whereas rates did not differ between brexpiprazole and placebo in the BEACON trial (6). Rates of other forms of neurologic side effects were similar to those for placebo in both studies, and no effect on cardiac conduction was detected. Brexpiprazole was not associated with blood pressure change, although the 8-day up-titration dosing schedule may have obscured such an effect. It is difficult to estimate from these data how brexpiprazole will compare with other available agents, particularly since the incidence of extrapyramidal symptoms and degree of weight gain or prolactin elevation are influenced by the subject sample and by persistent effects of previous medications.

In summary, as we learned from the CATIE study (7), we will not know with any certainty how a new antipsychotic compares with other agents currently on the market until more comparative data are available, ideally from head-to-head randomized trials. This information is important not only to justify the higher cost compared with generic agents but also to guide shared decision making. It is an appealing notion that a clinician could select from a collection of D2 partial agonists with a range of intrinsic activities the agent most suitable for an individual patient on the basis of sensitivity to side effects and efficacy requirements. Is a patient likely to experience a Goldilocks response and find brexpiprazole to be “just right” after disappointing experiences with aripiprazole and D2 antagonists? Possibly, but it’s not clear that the space that brexpiprazole occupies between aripiprazole and D2 antagonist antipsychotics is wide enough to be clinically relevant; whether brexpiprazole will differentiate itself from other agents in head-to-head comparisons or in clinical practice remains to be seen.

From the Department of Psychiatry, New York University Medical Center, New York; and the Nathan Kline Institute for Psychiatric Research, Orangeburg, N.Y.
Address correspondence to Dr. Goff ().

Dr. Goff reports no financial relationships with commercial interests.

References

1 Correll CU, Skuban A, Ouyang J, et al.: Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172:870–880LinkGoogle Scholar

2 Slade EP, Simoni-Wastila L: Forecasting Medicaid expenditures for antipsychotic medications. Psychiatr Serv 2015; 66:713–718LinkGoogle Scholar

3 Casey DE, Sands EE, Heisterberg J, et al.: Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 2008; 200:317–331Crossref, MedlineGoogle Scholar

4 Leucht S, Cipriani A, Spineli L, et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382:951–962Crossref, MedlineGoogle Scholar

5 Maeda K, Sugino H, Akazawa H, et al.: Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350:589–604Crossref, MedlineGoogle Scholar

6 Kane JM, Skuban A, Ouyang J, et al.: A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015; 164:127–135Crossref, MedlineGoogle Scholar

7 Lieberman JA: Comparative effectiveness of antipsychotic drugs: a commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 2006; 63:1069–1072Crossref, MedlineGoogle Scholar